advancing A-002 through Phase 3

EX-10.19 7 f53438a2exv10w19.htm EX-10.19 exv10w19
Exhibit 10.19
AMENDMENT NO. 1 TO
STOCK PURCHASE AGREEMENT
AND
ESCROW AGREEMENT
     This Amendment No. 1 (the “Amendment”) to (i) the Stock Purchase Agreement, dated as of September 25, 2009 (the “Purchase Agreement”), by and among Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and the investors listed on Exhibit A thereto (the “Investors”), and (ii) the Escrow Agreement, dated as of September 25, 2009 (the “Escrow Agreement”), by and among the Company, the Investors and Fremont Bank (the “Escrow Agent”), is made as of November 3, 2009 by and among the Company, the Investors, the Escrow Agent and Shionogi & Co., Ltd. (“Shionogi”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Purchase Agreement.
RECITALS
     WHEREAS, the Company desires to sell, and Shionogi desires to purchase, additional shares of the Company’s Common Stock, par value $0.001 per share, equal to $500,000 (the “Additional Investment”) divided by the Purchase Price (the “Additional Shares”) pursuant to the terms of the Purchase Agreement, as amended by this Amendment;
     WHEREAS, the Company and the Investors desire to amend the Purchase Agreement to allow for the sale of the Additional Shares to Shionogi under the terms of the Purchase Agreement, as amended by this Amendment;
     WHEREAS, the Company, the Investors and the Escrow Agent desire to amend the Escrow Agreement to allow for the inclusion of the Additional Investment as Escrowed Funds (as defined therein) under the terms of the Escrow Agreement, as amended by this Amendment;
     WHEREAS, Section 7.9 of the Purchase Agreement provides that the Purchase Agreement may be amended with the written consent of the Company and the Investors; and
     WHEREAS, Section 2.1 of the Escrow Agreement provides that the Escrow Agreement may be amended with the written consent of the Company, the Investors and the Escrow Agent.
     NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which the parties hereby acknowledge, the parties hereto agree as follows:
AGREEMENT
     1. Section 1.1 of the Purchase Agreement is hereby amended and restated in its entirety as follows:
          “1.1 Authorization and Escrow. The Company will, prior to the Closing (as defined below), authorize the sale and issuance to the Investors of a number of shares of the Company’s Common Stock (the

 


 

Shares”), par value $0.001 per share, equal to $20,500,000 divided by the Purchase Price (as defined below). On or prior to September 28, 2009, each Investor shall deposit with Fremont Bank (the “Escrow Agent”), pursuant to the Escrow Agreement attached as Exhibit B (the “Escrow Agreement”), the amount set forth opposite such Investor’s name on the Schedule of Investors, to be held in escrow (and not as the Company’s property) for release at the Closing (or if earlier, for payment to the Investors, as provided in the Escrow Agreement); provided, however, that Shionogi & Co., Ltd. (“Shionogi”) shall deposit such amount with the Escrow Agent no later than two (2) business days following the execution of Amendment No. 1 to this Agreement by each of the parties thereto.”
     2. Exhibit A to the Purchase Agreement is hereby amended and restated in its entirety to read as set forth on Exhibit A-1 hereto.
     3. The first recital of the Escrow Agreement is hereby amended and restated in its entirety as follows:
          “WHEREAS, the Purchasers will be purchasing from the Company, severally and not jointly with the other Purchasers, with the Purchasers’ funds (hereinafter the “Subscription Amounts”), in the aggregate, $20,500,000 of the Company’s Common Stock (the “Securities”) at the Closing as set forth in the Stock Purchase Agreement between the Purchasers and the Company (the “Purchase Agreement”);”
     4. Section 1.4 of the Escrow Agreement is hereby amended and restated in its entirety as follows:
          “1.4. Deposit of Funds. Each Purchaser shall deposit with the Escrow Agent, on or prior to September 28, 2009, such Purchaser’s Subscription Amount as set forth on Exhibit A hereto; provided, however, that Shionogi & Co., Ltd. (“Shionogi”) shall deposit such amount with the Escrow Agent no later than two (2) business days following the execution of Amendment No. 1 to this Agreement by each of the parties thereto. Wire transfers to the Escrow Agent shall be made as follows:
Domestic Instructions
Fremont Bank
Beneficiary Name
: Fremont Bank as Escrow Agent for Anthera Pharmaceuticals, Inc.
Fremont Bank Account Number
ABA# 121107882
International Wires
Swift: BOFAUS3N
Correspondent Bank: Bank of America
Correspondent Bank ABA: 026009593

2


 

     5. Exhibit A to the Escrow Agreement is hereby amended and restated in its entirety to read as set forth on Exhibit A-2 hereto.
     6. Shionogi and the other parties to this Amendment agree and acknowledge that, upon execution of this Amendment, Shionogi shall be considered an “Investor” under the Purchase Agreement and a “Purchaser” under the Escrow Agreement, each as amended by this Amendment, for all purposes. The Company represents and warrants to Shionogi that, except as set forth on the Schedule of Exceptions, the representations and warranties set forth in Section 3 of the Purchase Agreement are true and correct as of the date hereof. Shionogi represents and warrants to the Company that, as to Shionogi, the representations and warranties set forth in Section 4 of the Purchase Agreement are true and correct as of the date hereof.
     7. This Amendment shall be governed by and construed under the laws of the State of California in all respects as such laws are applied to agreements among California residents entered into and performed entirely within California, without giving effect to conflict of law principles thereof.
     8. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
     9. Except as specifically amended hereby, each of the Purchase Agreement and the Escrow Agreement shall remain in full force and effect.
(Signature Pages Follow)

3


 

     IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 as of the date first written above.
                 
COMPANY:       SHIONOGI:
 
               
ANTHERA PHARMACEUTICALS, INC.       SHIONOGI & CO., LTD.
 
               
By:
  /s/ Paul F. Truex       By:   /s/ Sachio Tokaji
 
               
 
  Paul F. Truex           Sachio Tokaji
 
  President and Chief Executive Officer           Director of the Board
 
              Senior Executive Officer
SIGNATURE PAGE TO ANTHERA PHARMACEUTICALS, INC.
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT AND ESCROW AGREEMENT

 


 

     IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 as of the date first written above.
         
    INVESTORS:
 
       
    VANTAGEPOINT VENTURE PARTNERS IV (Q), L.P.
    VANTAGEPOINT VENTURE PARTNERS IV, L.P.
    VANTAGEPOINT VENTURE PARTNERS IV PRINCIPALS
           FUND, L.P.
 
       
 
  By:   VantagePoint Venture Associates IV,
 
      L.L.C., its General Partner
 
       
 
  By:   /s/ Alan E. Salzman
 
       
 
       
 
  Name:   Alan E. Salzman
 
  Title:   Managing Member
SIGNATURE PAGE TO ANTHERA PHARMACEUTICALS, INC.
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT AND ESCROW AGREEMENT

 


 

     IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 as of the date first written above.
         
    INVESTORS:
 
       
    SOFINNOVA VENTURE PARTNERS VI, L.P.,
 
       
    as nominee for
    SOFINNOVA VENTURE PARTNERS VI, L.P.
    SOFINNOVA VENTURE PARTNERS VI GMBH CO. K.G.
    SOFINNOVA VENTURE AFFILIATES VI, L.P.
 
       
 
  By:   Sofinnova Management VI, LLC
 
      Its General Partner
 
       
 
  By:   /s/ James Healy
 
       
 
  Name:   James Healy
 
  Title:   Managing Member
SIGNATURE PAGE TO ANTHERA PHARMACEUTICALS, INC.
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT AND ESCROW AGREEMENT

 


 

     IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 as of the date first written above.
         
    INVESTORS:
 
       
    A. M. PAPPAS LIFE SCIENCE VENTURES III, L.P.
 
       
 
  By:   /s/ Ford S. Worthy
 
       
 
  Name:   Ford S. Worthy
 
  Title:   Partner & CEO
 
       
    PV III CEO FUND, L.P.
 
       
 
  By:   /s/ Ford S. Worthy
 
       
 
  Name:   Ford S. Worthy
 
  Title:   Partner & CEO
SIGNATURE PAGE TO ANTHERA PHARMACEUTICALS, INC.
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT AND ESCROW AGREEMENT

 


 

     IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 as of the date first written above.
         
    INVESTORS:
 
       
    CAXTON ADVANTAGE LIFE SCIENCES FUND, L.P.
 
       
 
  By:   Caxton Advantage Venture Partners, L.P.,
Its General Partner
 
       
 
  By:   Advantage Life Science Partners, LLC,
Its Managing Partner
 
       
 
  By:   /s/ A. Rachel Leheny
 
       
 
  Name:   A. Rachel Leheny
 
  Title:   Member
SIGNATURE PAGE TO ANTHERA PHARMACEUTICALS, INC.
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT AND ESCROW AGREEMENT

 


 

     IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 as of the date first written above.
         
    INVESTORS:
 
       
    HBM BIOCAPITAL
 
       
    HBM BioCapital (EUR) L.P.
 
  By:   HBM BioCapital Ltd.
 
  Its:   General Partner
 
       
 
      /s/ John Arnold
 
       
 
  By:   John Arnold
 
  Its:   Chairman & Managing Director
 
       
    HBM BioCapital (USD) L.P.
 
  By:   HBM BioCapital Ltd.
 
  Its:   General Partner
 
       
 
      /s/ John Arnold
 
       
 
  By:   John Arnold
 
  Its:   Chairman & Managing Director
SIGNATURE PAGE TO ANTHERA PHARMACEUTICALS, INC.
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT AND ESCROW AGREEMENT

 


 

     IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 as of the date first written above.
         
    ESCROW AGENT:
 
       
    FREMONT BANK
 
       
 
  By:   /s/ Andrew Mastorakis
 
       
 
      Andrew Mastorakis
 
      President
SIGNATURE PAGE TO ANTHERA PHARMACEUTICALS, INC.
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT AND ESCROW AGREEMENT

 


 

EXHIBIT A-1
SCHEDULE OF INVESTORS
           
Investor   Aggregate Purchase Price  
VantagePoint Venture Partners IV (Q), L.P.
  $ 8,280,659.71    
1001 Bayhill Drive, Suite 300
San Bruno, CA 94066
         
VantagePoint Venture Partners IV, L.P.
  $ 828,979.95    
1001 Bayhill Drive, Suite 300
San Bruno, CA 94066
         
VantagePoint Venture Partners IV Principals Fund, L.P.
  $ 30,161.34    
1001 Bayhill Drive, Suite 300
San Bruno, CA 94066
         
Sofinnova Venture Partners VI, L.P.
  $ 5,902,150.00    
140 Geary Street, 10th Floor
San Francisco, CA 94108
         
A. M. Pappas Life Science Ventures III, L.P.
  $ 1,451,117.95    
P.O. Box 110287
Research Triangle Park, NC 27709
         
PV III CEO Fund, L.P.
  $ 90,165.05    
P.O. Box 110287
Research Triangle Park, NC 27709
         
Caxton Advantage Life Sciences Fund, L.P.
  $ 1,708,383.00    
500 Park Avenue
New York, NY 10022
Attention: Rachel Leheny
Email: ***@***
         
HBM BioCapital (EUR) L.P.
  $ 1,452,125.55    
John Arnold
HBM BioCapital Ltd.
Centennial Towers, 3rd Floor
2454 West Bay Road
Grand Cayman
Cayman Islands
         
HBM BioCapital (USD) L.P.
  $ 256,257.45    
John Arnold
HBM BioCapital Ltd.
Centennial Towers, 3rd Floor
2454 West Bay Road
Grand Cayman
Cayman Islands
         
Shionogi & Co., Ltd.
  $ 500,000.00    
1-8 Doshomachi 3-chome
Chuo-ku, Osaka
Japan
         
TOTAL
  $ 20,500,000.00    

 


 

EXHIBIT A-2
SCHEDULE OF PURCHASERS
                 
Purchaser   Subscription Amount   Subscription %
VantagePoint Venture Partners IV (Q), L.P.
  $ 8,280,659.71       40.39 %
1001 Bayhill Drive, Suite 300
San Bruno, CA 94066
               
VantagePoint Venture Partners IV, L.P.
  $ 828,979.95       4.04 %
1001 Bayhill Drive, Suite 300
San Bruno, CA 94066
               
VantagePoint Venture Partners IV Principals Fund, L.P.
  $ 30,161.34       0.15 %
1001 Bayhill Drive, Suite 300
San Bruno, CA 94066
               
Sofinnova Venture Partners VI, L.P.
  $ 5,902,150.00       28.79 %
140 Geary Street, 10th Floor
San Francisco, CA 94108
               
A. M. Pappas Life Science Ventures III, L.P.
  $ 1,451,117.95       7.08 %
P.O. Box 110287
Research Triangle Park, NC 27709
               
PV III CEO Fund, L.P.
  $ 90,165.05       0.44 %
P.O. Box 110287
Research Triangle Park, NC 27709
               
Caxton Advantage Life Sciences Fund, L.P.
  $ 1,708,383.00       8.33 %
500 Park Avenue
New York, NY 10022
Attention: Rachel Leheny
Email: ***@***
               
HBM BioCapital (EUR) L.P.
  $ 1,452,125.55       7.08 %
John Arnold
HBM BioCapital Ltd.
Centennial Towers, 3rd Floor
2454 West Bay Road
Grand Cayman
Cayman Islands
               
HBM BioCapital (USD) L.P.
  $ 256,257.45       1.25 %
John Arnold
HBM BioCapital Ltd.
Centennial Towers, 3rd Floor
2454 West Bay Road
Grand Cayman
Cayman Islands
               
Shionogi & Co., Ltd.
  $ 500,000.00       2.44 %
1-8 Doshomachi 3-chome
Chuo-ku, Osaka
Japan
               
TOTAL
  $ 20,500,000.00       100.00 %